Retraction: Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies (BioMed Research International (2014) 2014 (203693) DOI: 10.1155/2014/203693);Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Bertino, Gaetano ^a   Demma, Shirin ^a   Ardiri, Annalisa ^a   Proiti, Maria ^a   Gruttadauria, Salvatore ^b   Toro, Adriana ^a   Malaguarnera, Giulia ^a   Bertino, Nicoletta ^a   Malaguarnera, Michele ^a   Malaguarnera, Mariano ^a   Di Carlo, Isidoro ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CD3 ANTIBODY; CYCLIN A2; CYCLIN D1; DECARBOXYPROTHROMBIN; DENDRITIC CELL VACCINE; ERLOTINIB; EVEROLIMUS; FARNOQUINONE; GEFITINIB; GLYPICAN 3; GROWTH FACTOR; LAPATINIB; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; VACCINE; ANTINEOPLASTIC AGENT; DCP1A PROTEIN, HUMAN; GLYPICAN; GPC3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RIBONUCLEASE; TRANSACTIVATOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; BIBLIOGRAPHIC DATABASE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MEDLINE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; ONCOGENE C MYC; OVERALL SURVIVAL; PORTAL HYPERTENSION; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYSTEMATIC REVIEW; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; HUMAN GENOME; IMMUNOTHERAPY; LIVER NEOPLASMS; METABOLISM; MUTATION; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; ENDORIBONUCLEASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMIC INSTABILITY; GLYPICANS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 84903835849     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2018/4560161     Document Type: Erratum

References (111)

1. C.-L. Lin and J.-H. Kao, "Risk stratification for hepatitis B virus related hepatocellular carcinoma," Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 10-17, 2013.
2. T. Umemura, T. Ichijo, K. Yoshizawa, E. Tanaka, and K. Kiyosawa, "Epidemiology of hepatocellular carcinoma in Japan," Journal of Gastroenterology, vol. 44, supplement 19, pp. 102-107, 2009.
3. J. A. Davila, J. R. Kramer, Z. Duan et al., "Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors," Hepatology, vol. 57, no. 5, pp. 1858-1868, 2013.
4. G. Baffy, E. M. Brunt, and S. H. Caldwell, "Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace," Journal of Hepatology, vol. 56, no. 6, pp. 1384-1391, 2012.
5. I. Di Carlo, M. Mannino, A. Toro et al., "Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature," World Journal of Surgical Oncology, vol. 10, article 79, 2012.
6. G. Bertino, A. M. Ardiri, M. M. Santonocito, and P. M. Boemi, "Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels," Panminerva Medica, vol. 51, no. 2, pp. 133-134, 2009.
7. G. Bertino, A. Ardiri, M. Malaguarnera, G. Malaguarnera, N. Bertino, and G. S. Calvagno, "Hepatocellualar carcinoma serum markers," Seminars in Oncology, vol. 39, no. 4, pp. 410-433, 2012.
8. G. Bertino, S. Neri, C. M. Bruno et al., "Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma," Minerva Medica, vol. 102, no. 5, pp. 363-371, 2011.
9. G. Bertino, A. M. Ardiri, G. S. Calvagno, N. Bertino, and P. M. Boemi, "Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer," Drug News and Perspectives, vol. 23, no. 8, pp. 498-508, 2010.
10. A. Biondi, G. Malaguarnera, M. Vacante et al., "Elevated serum levels of Chromogranin A in hepatocellular carcinoma," BMC Surgery, vol. 12, supplement 1, article S7, 2012.
11. G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera, G. Bertino, and M. Berretta, "Serum markers of intrahepatic cholangiocarcinoma," Disease Markers, vol. 34, no. 4, pp. 219-228, 2013.
12. G. Bertino, A. Ardiri, S. Demma et al., "Rare benign tumors of the liver: still rare?" Journal of Gastrointestinal Cancer, vol. 45, no. 2, pp. 202-217, 2014.
13. G. Bertino, A. M. Ardiri, P. M. Boemi et al., "A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma," Panminerva Medica, vol. 50, no. 3, pp. 221-226, 2008.
14. G. Bertino, A. M. Ardiri, G. S. Calvagno et al., "Carbohydrate 19.9 antigen serum levels in liver disease," BioMed Research International, vol. 2013, Article ID 531640, 6 pages, 2013.
15. C. Della Corte and M. Colombo, "Surveillance for hepatocellular carcinoma," Seminars in Oncology, vol. 39, no. 4, pp. 384-398, 2012.
16. N. Bolog, G. Andreisek, I. Oancea, and A. Mangrau, "CT and MR imaging of hepatocellular carcinoma," Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 2, pp. 181-189, 2011.
17. J. M. Llovet, C. Brú, and J. Bruix, "Prognosis of hepatocellular carcinoma: the BCLC staging classification," Seminars in Liver Disease, vol. 19, no. 3, pp. 329-337, 1999. (Pubitemid 29488775)
18. P. Giunchedi, M. Maestri, E. Gavini, P. Dionigi, and G. Rassu, "Transarterial chemoembolization of hepatocellular carcinoma-agents and drugs: an overview. Part 2," Expert Opinion on Drug Delivery, vol. 10, no. 6, pp. 799-810, 2013.
19. P. M. Lopez, A. Villanueva, and J. M. Llovet, "Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials," Alimentary Pharmacology and Therapeutics, vol. 23, no. 11, pp. 1535-1547, 2006. (Pubitemid 43727460)
20. M. A. Wörns, A. Weinmann, M. Schuchmann, and P. R. Galle, "Systemic therapies in hepatocellular carcinoma," Digestive Diseases, vol. 27, no. 2, pp. 175-188, 2009.
21. C. Huang, D. Xu, Q. Xia, P. Wang, C. Rong, and Y. Su, "Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II," Journal of Pharmacy and Pharmacology, vol. 64, no. 12, pp. 1741-1750, 2012.
22. T. Yau, P. Chan, R. Epstein, and R. T. Poon, "Evolution of systemic therapy of advanced hepatocellular carcinoma," World Journal of Gastroenterology, vol. 14, no. 42, pp. 6437-6441, 2008.
23. C. Verhoef, H. Van Dekken, L. J. Hofland et al., "Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics," Digestive Surgery, vol. 25, no. 1, pp. 21-26, 2008. (Pubitemid 351560591)
24. S. Becker, V. Ardisson, N. Lepareur et al., "Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen," Nuclear Medicine and Biology, vol. 37, no. 7, pp. 777-784, 2010.
25. J. Bruix and M. Sherman, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update," Hepatology, vol. 53, no. 3, pp. 1020-1022, 2011.
26. J. M. Llovet, S. Ricci, V. Mazzaferro et al., "Sorafenib in advanced hepatocellular carcinoma," New England Journal of Medicine, vol. 359, no. 4, pp. 378-390, 2008.
27. A. Villanueva, P. Newell, D. Y. Chiang, S. L. Friedman, and J. M. Llovet, "Genomics and signaling pathways in hepatocellular carcinoma," Seminars in Liver Disease, vol. 27, no. 1, pp. 55-76, 2007.
28. A. Patel and W. Sun, "Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future," Current Treatment Options in Oncology, 2014.
29. S. Tanaka and S. Arii, "Molecular targeted therapies in hepatocellular carcinoma," Seminars in Oncology, vol. 39, no. 4, pp. 486-492, 2012.
30. D. Y. Chiang, A. Villanueva, Y. Hoshida et al., "Focal gains of VEGFA and molecular classification of hepatocellular carcinoma," Cancer Research, vol. 68, no. 16, pp. 6779-6788, 2008.
31. P. A. Farazi, J. Glickman, S. Jiang, A. Yu, K. L. Rudolph, and R. A. DePinho, "Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma," Cancer Research, vol. 63, no. 16, pp. 5021-5027, 2003. (Pubitemid 37022640)
32. S.-A. Ng and C. Lee, "Hepatitis B virus X gene and hepatocarcinogenesis," Journal of Gastroenterology, vol. 46, no. 8, pp. 974-990, 2011.
33. C. Miroux, T. Vausselin, and N. Delhem, "Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response," Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1563-1572, 2010.
34. D. Petrovic, Z. Stamataki, E. Dempsey et al., "Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion," Hepatology, vol. 53, no. 6, pp. 1846-1853, 2011.
35. A. Villanueva, S. Toffanin, and J. M. Llovet, "Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps," Current Opinion in Oncology, vol. 20, no. 4, pp. 444-453, 2008.
36. S. Boyault, D. S. Rickman, A. De Reyniès et al., "Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets," Hepatology, vol. 45, no. 1, pp. 42-52, 2007. (Pubitemid 46144363)
37. H. Huynh, T. T. Tuyen Nguyen, K.-H. Pierce Chow, P. H. Tan, K. C. Soo, and E. Tran, "Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis," BMC Gastroenterology, vol. 3, article 19, 2003.
38. M. D. Desai, B. S. Saroya, and A. C. Lockhart, "Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers," Expert Opinion on Investigational Drugs, vol. 22, no. 3, pp. 341-356, 2013.
39. L. Goyal, M. D. Muzumdar, and A. X. Zhu, "Targeting the HGF/c-MET pathway in hepatocellular carcinoma," Clinical Cancer Research, vol. 19, no. 9, pp. 2310-2318, 2013.
40. Y. Chao, C.-P. Li, G.-Y. Chau et al., "Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery," Annals of Surgical Oncology, vol. 10, no. 4, pp. 355-362, 2003. (Pubitemid 40486931)
41. R. T. P. Poon, J. W. Y. Ho, C. S. W. Tong, C. Lau, I. O. L. Ng, and S.-T. Fan, "Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma," British Journal of Surgery, vol. 91, no. 10, pp. 1354-1360, 2004. (Pubitemid 39331462)
42. R. J. Epstein, "VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic," Cancer and Metastasis Reviews, vol. 26, no. 3-4, pp. 443-452, 2007.
43. N. K. Saxena, D. Sharma, X. Ding et al., "Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells," Cancer Research, vol. 67, no. 6, pp. 2497-2507, 2007. (Pubitemid 46548934)
44. J. M. Llovet and J. Bruix, "Molecular targeted therapies in hepatocellular carcinoma," Hepatology, vol. 48, no. 4, pp. 1312-1327, 2008.
45. T. Ishiguro, M. Sugimoto, Y. Kinoshita et al., "Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer," Cancer Research, vol. 68, no. 23, pp. 9832-9838, 2008.
46. W. Piao, Y. Wang, Y. Adachi et al., "Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas," Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1483-1493, 2008.
47. E. Unitt, A. Marshall, W. Gelson et al., "Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation," Journal of Hepatology, vol. 45, no. 2, pp. 246-253, 2006.
48. T. Takayama, T. Sekine, M. Makuuchi et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial," The Lancet, vol. 356, no. 9232, pp. 802-807, 2000.
49. R. Thimme, M. Neagu, T. Boettler et al., "Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma," Hepatology, vol. 48, no. 6, pp. 1821-1833, 2008.
50. H. Komori, T. Nakatsura, S. Senju et al., "Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma," Clinical Cancer Research, vol. 12, no. 9, pp. 2689-2697, 2006.
51. X.-Y. Shang, H.-S. Chen, H.-G. Zhang et al., "The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients," Clinical Cancer Research, vol. 10, no. 20, pp. 6946-6955, 2004. (Pubitemid 39383045)
52. G. Bricard, H. Bouzourene, O. Martinet et al., "Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma," Journal of Immunology, vol. 174, no. 3, pp. 1709-1716, 2005.
53. E. Mizukoshi, Y. Nakamoto, Y. Marukawa et al., "Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma," Hepatology, vol. 43, no. 6, pp. 1284-1294, 2006. (Pubitemid 43980107)
54. E. Unitt, S. M. Rushbrook, A. Marshall et al., "Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of Tregulatory cells," Hepatology, vol. 41, no. 4, pp. 722-730, 2005. (Pubitemid 40462933)
55. B. Hoechst, L. A. Ormandy, M. Ballmaier et al., "A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells," Gastroenterology, vol. 135, no. 1, pp. 234-243, 2008. (Pubitemid 351899008)
56. K. Fujiwara, T. Higashi, K. Nouso et al., "Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma," Journal of Gastroenterology and Hepatology, vol. 19, no. 10, pp. 1121-1127, 2004. (Pubitemid 39371253)
57. K. Kurokohchi, M. Carrington, D. L. Mann et al., "Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma," Hepatology, vol. 23, no. 5, pp. 1181-1188, 1996. (Pubitemid 26137065)
58. T. Tatsumi, T. Takehara, K. Katayama et al., "Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma," Hepatology, vol. 25, no. 5, pp. 1108-1114, 1997. (Pubitemid 27199936)
59. F. Shi, M. Shi, Z. Zeng et al., "PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients," International Journal of Cancer, vol. 128, no. 4, pp. 887-896, 2011.
60. S. Behboudi, A. Alisa, S. Boswell, J. Anastassiou, A. A. Pathan, and R. Williams, "Expansion of anti-AFPTh1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease," British Journal of Cancer, vol. 102, no. 4, pp. 748-753, 2010.
61. E. Breous and R. Thimme, "Potential of immunotherapy for hepatocellular carcinoma," Journal of Hepatology, vol. 54, no. 4, pp. 830-834, 2011.
62. K. Teramoto, Y. Ohshio, T. Fujita, J. Hanaoka, and K. Kontani, "Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancerimmunotherapy," Journal of Cancer Research and Clinical Oncology, vol. 139, no. 5, pp. 861-870, 2013.
63. J. M. O'Bryan, J. A. Potts, H. L. Bonkovsky, A. Mathew, and A. L. Rothman, "Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes," PLoS ONE, vol. 6, no. 8, Article ID e20922, 2011.
64. A. D. Pardee and L. H. Butterfield, "Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities," Oncoimmunology, vol. 1, no. 1, pp. 48-55, 2012.
65. T. Stroffolini, A. Spadaro, V. Di Marco et al., "Current practice of chronic hepatitis B treatment in Southern Italy," European Journal of Internal Medicine, vol. 23, no. 5, pp. e124-e127, 2012.
66. G. Bertino, A. Ardiri, P. M. Boemi et al., "Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis," European Journal of Clinical Pharmacology, vol. 66, no. 10, pp. 1055-1063, 2010.
67. F. Zhao, F. Korangy, and T. F. Greten, "Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma," Digestive Diseases, vol. 30, no. 5, pp. 477-482, 2012.
68. L. Cai, Z. Zhang, L. Zhou et al., "Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients," Clinical Immunology, vol. 129, no. 3, pp. 428-437, 2008.
69. M. El Ansary, S. Mogawer, S. A. Elhamid et al., "Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC," Journal of Cancer Research and Clinical Oncology, vol. 139, no. 1, pp. 39-48, 2013.
70. B. Xie, D. H. Wang, and S. J. Spechler, "Sorafenib for treatment of hepatocellular carcinoma: a systematic review," Digestive Diseases and Sciences, vol. 57, no. 5, pp. 1122-1129, 2012.
71. G. G. Di Costanzo, R. Tortora, L. Iodice et al., "Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice," Digestive and Liver Disease, vol. 44, no. 9, pp. 788-792, 2012.
72. A.-L. Cheng, Y.-K. Kang, Z. Chen et al., "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial," The Lancet Oncology, vol. 10, no. 1, pp. 25-34, 2009.
73. M. A. Wörns, M. Schuchmann, C. Düber, G. Otto, P. R. Galle, and A. Weinmann, "Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment," Oncology, vol. 79, no. 1-2, pp. 85-92, 2010.
74. A. X. Zhu, D. V. Sahani, E. di Tomaso et al., "Sunitinib monotherapy in patients with advanced heaptocellular carcinoma: insights from a multidisciplinary phase II study," Journal of Clinical Oncology, vol. 26, supplement, abstract 4521, 2008.
75. D. Hoda, C. Catherine, J. Strosberg et al., "Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma," Gastrointestinal Cancers Symposium, abstarct 267, 2008.
76. H. Huynh, S. P. Choo, H. C. Toh et al., "Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation," Current Cancer Drug Targets, vol. 11, no. 8, pp. 944-953, 2011.
77. C. M. Bagi, D. F. Gebhard, and C. J. Andresen, "Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma," European Journal of Gastroenterology and Hepatology, vol. 24, no. 5, pp. 563-574, 2012.
78. R. Finn, "Emerging targeted strategies in advanced hepatocellular carcinoma," Seminars in Liver Disease, vol. 33, supplement 1, pp. S11-S19, 2013.
79. H. C. Toh, P.-J. Chen, B. I. Carr et al., "Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma," Cancer, vol. 119, no. 2, pp. 380-387, 2013.
80. C. Cainap, S. Qin, W. T. Huang et al., "Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)," Journal of Clinical Oncology, vol. 31, supplement 4, abstract 249, 2013.
81. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. V. Woude, "Targeting MET in cancer: rationale and progress," Nature Reviews Cancer, vol. 12, no. 2, pp. 89-103, 2012.
82. N. Munshi, S. Jeay, Y. Li et al., "ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity," Molecular Cancer Therapeutics, vol. 9, no. 6, pp. 1544-1553, 2010.
83. S. Previdi, G. Abbadessa, F. Dalò, D. S. France, and M. Broggini, "Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ197) and shRNA c-MET knockdown," Molecular Cancer Therapeutics, vol. 11, no. 1, pp. 214-223, 2012.
84. A. Santoro, L. Rimassa, I. Borbath et al., "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study," The Lancet Oncology, vol. 14, no. 1, pp. 55-63, 2013.
85. A. Santoro, C. Porta, L. Rimassa et al., "Metiv-HCC: a phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC)," Journal of Clinical Oncology, vol. 31, supplement, abstract TPS4159, 2013.
86. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," New England Journal of Medicine, vol. 350, no. 23, pp. 2335-2342, 2004. (Pubitemid 38702844)
87. R. Wang, N. Zhao, S. Li et al., "MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42," Hepatology, vol. 58, no. 2, pp. 642-653, 2013.
88. T. Chou and R. S. Finn, "Brivanib: a review of development," Future Oncology, vol. 8, no. 9, pp. 1083-1090, 2012.
89. R. S. Finn, "Overview and description of hepatocellular carcinoma," Clinical Advances in Hematology and Oncology, vol. 5, no. 4, pp. 4-7, 2013.
90. R. S. Finn, Y.-K. Kang, M. Mulcahy et al., "Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma," Clinical Cancer Research, vol. 18, no. 7, pp. 2090-2098, 2012.
91. J. M. Llovet, T. Decaens, J. L. Raoul et al., "Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study," Journal of Clinical Oncology, vol. 31, no. 28, pp. 3509-3516, 2013.
92. C. Verslype, A. L. Cohn, R. K. Kelley et al., "Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a Phase 2 randomized discontinuation trial (RDT)," Journal of Clinical Oncology, vol. 30, supplement, abstract 4007, 2012.
93. A. X. Zhu, M. Kudo, M. Eric Assenat et al., "EVOLVE-1: phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib," Journal of Clinical Oncology, vol. 32, supplement 3, abstract 172, 2014.
94. J. J. Knox, R. Qin, and J. R. Strosberg, "A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC)," Journal of Clinical Oncology, vol. 30, supplement, abstract 4099, 2012.
95. J.-H. Zhong, L. Ma, L.-C. Wu et al., "Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review," International Journal of Clinical Practice, vol. 66, no. 1, pp. 21-27, 2012.
96. W.-C. Lee, H.-C. Wang, C.-F. Hung, P.-F. Huang, C.-R. Lia, and M.-F. Chen, "Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial," Journal of Immunotherapy, vol. 28, no. 5, pp. 496-504, 2005. (Pubitemid 41232571)
97. H. Kayashima, T. Toshima, S. Okano et al., "Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice," Journal of Immunology, vol. 185, no. 1, pp. 698-708, 2010.
98. N. Schmidt, C. Neumann-Haefelin, and R. Thimme, "Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy," Digestive Diseases, vol. 30, no. 5, pp. 483-491, 2012.
99. E. Mizukoshi, Y. Nakamoto, K. Arai et al., "Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma," Hepatology, vol. 53, no. 4, pp. 1206-1216, 2011.
100. K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson, "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity," Journal of Experimental Medicine, vol. 207, no. 10, pp. 2187-2194, 2010.
101. A. D. Pardee, D. McCurry, S. Alber, P. Hu, A. L. Epstein, and W. J. Storkus, "A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment," Cancer Research, vol. 70, no. 22, pp. 9041-9052, 2010.
102. K. M. Kee, C. H. Hung, J. H. Wang, and S. N. Lu, "Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib," OncoTargets and Therapy, vol. 7, pp. 829-834, 2014.
103. A. X. Zhu, D. G. Duda, D. V. Sahani, and R. K. Jain, "HCC and angiogenesis: possible targets and future directions," Nature Reviews Clinical Oncology, vol. 8, no. 5, pp. 292-301, 2011.
104. J. Heo, T. Reid, L. Ruo et al., "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer," Nature Medicine, vol. 19, no. 3, pp. 329-336, 2013.
105. W. Wang, L. Liu, H. Chen et al., "EASL- and mRECIST-evaluated responses to combination therapy predict survival in patients with hepatocellular carcinoma," Clinical Cancer Research, 2014.
106. F. Y. Yao, "Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment?" Liver Transplantation, vol. 20, no. 3, pp. 257-260, 2014.
107. N. Mehta, J. L. Dodge, J. P. Roberts, R. Hirose, and F. Y. Yao, "Outcome after liver transplantation in patients with hepatocellular carcinoma with a low risk of dropout from the transplant waiting list," Liver Transplantation, 2014.
108. G. K. Abou-Alfa, "Sorafenib use in hepatocellular carcinoma: more questions than answers," Hepatology, 2014.
109. T. Arizumi, K. Ueshima, H. Takeda et al., "Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma," Journal of Gastroenterology, 2014.
110. G. Bertino, I. Di Carlo, A. Ardiri et al., "Systemic therapies in hepatocellular carcinoma: present and future," Future Oncology, vol. 9, no. 10, pp. 1533-1548, 2013.
111. G. Bertino, S. Demma, N. Bertino, and A. Ardiri, "Management of hepatocellular carcinoma: an update at the start of 2014," Journal of Gastrointestinal & Digestive System, vol. 4, no. 2, pp. 1-7, 2014.